Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute...

Area of Science:

• Cardiovascular Research
• Pharmacology
• Medical Imaging

Background:

• High-density lipoproteins (HDLs) possess protective vascular effects, yet therapies targeting HDL have largely failed in clinical trials.
• Previous studies indicate potential benefits of HDL-targeting agents, prompting further investigation.

Purpose of the Study:

• To evaluate the efficacy of CER-001, an HDL-mimetic agent, in reducing coronary atherosclerosis.
• To assess the impact of CER-001 on atheroma volume and coronary stenosis using intravascular ultrasonography (IVUS) and quantitative coronary angiography (QCA).

Main Methods:

• A prospective, double-blinded, randomized trial involving 507 patients across 51 centers.
• Patients received weekly infusions of placebo or CER-001 (3, 6, or 12 mg/kg) for six weeks.
• Coronary atherosclerosis was assessed using IVUS and QCA at baseline and after treatment.

Main Results:

• CER-001 treatment did not significantly alter total atheroma volume or percent atheroma volume compared to placebo.
• No significant differences were observed in coronary artery scores or cumulative coronary stenosis scores between CER-001 groups and placebo.
• Major cardiovascular event rates were similar across all treatment groups, including placebo.

Conclusions:

• Weekly infusions of CER-001 did not demonstrate a reduction in coronary atherosclerosis as measured by IVUS and QCA.
• The study suggests that CER-001, in this specific regimen and population, is not effective in treating atherosclerosis.
• Further investigation into alternative dosing strategies or patient populations for CER-001 is warranted.